Follicle-Stimulating Hormone (FSH) Levels During Androgen Deprivation Therapy Are Not Associated With Survival or Development of Castration-Resistant Prostate Cancer
Abstract
Background Follicle-stimulating hormone (FSH) dysregulation plays a potential role
in prostate cancer progression.
The objective of this study was to evaluate whether higher FSH levels during androgen
deprivation therapy (ADT) for
recurrent prostate cancer could predict the development of castration-resistant prostate
cancer (CRPC), prostate
cancer-specific survival (CSS), and overall survival (OS).
Methods Serum FSH levels were measured in cryopreserved samples of the continuous
ADT arm of the PR.7 trial,
supplemented with analogous samples from a large contemporaneous biobank. Univariate
and multivariate analyses
assessed the relationship between FSH tertiles and time to CRPC, as well as CSS, and
OS.
Results A total of 172 patients were included in our analysis. Of these, 54 patients
(31%) developed CRPC during
the 9-year follow-up. Median FSH for the tertiles was 4.35, 6.13, and 11.32 mIU/mL.
FSH tertiles were not significantly
associated with the time to CRPC, or with CSS or OS. FSH levels were not a significant
prognostic factor for these
oncologic outcomes.
Conclusion As previously reported, the use of gonadotropin-releasing hormone (GnRH)
antagonists for ADT
has significantly more suppression of FSH levels than GnRH agonists. Our results do
not suggest that differences in
circulating FSH 1 year following ADT initiation influence long-term oncologic outcomes
or development of CRPC.
Type
Journal articlePermalink
https://hdl.handle.net/10161/24533Published Version (Please cite this version)
10.48083/LWHQ7760Publication Info
Atchia, Kaleem; Joncas, France-Helene; Trasiewicz, Lily Summers; Tan, Wei Phin; Ding,
Keyue; Inman, Brant A; & Toren, Paul (n.d.). Follicle-Stimulating Hormone (FSH) Levels During Androgen Deprivation Therapy Are
Not Associated With Survival or Development of Castration-Resistant Prostate Cancer.
Soc Int Urol J, 3(2). pp. 56-61. 10.48083/LWHQ7760. Retrieved from https://hdl.handle.net/10161/24533.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Brant Allen Inman
Professor of Surgery
Clinical research interests: Clinical trials of novel diagnostic tests and therapies
for genitourinary malignancies, with a strong focus on bladder cancer. Basic science
research interests: Immune therapies for cancer, hyperthermia and heat-based treatment
of cancer, molecular biology of genitourinary cancers, novel diagnostics and therapies
for genitourinary cancers

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info